natgillin/translations-raw huggingface dataset:
In-vitro-interaktionsstudier viste, at liposomal og non-liposomal mifamurtid ikke hæmmer den metaboliske aktivitet af cytokrom P450 i poolede humane levermikrosomer.
In vitro interaction studies showed that liposomal and non-liposomal mifamurtide do not inhibit the metabolic activity of cytochrome P450 in pooled human liver microsomes.
Ved meget høje doser blev der observeret blødninger hos dyr.
Haemorrhage was observed in animals at very high doses.
Det frysetørrede pulver bør inden opløsning, filtrering og fortynding nå en temperatur på mellem ca. 20 C - 25 °C.
The lyophilised powder should be allowed to reach a temperature between approximately 20 C-25 °C prior to reconstitution, filtering using the filter provided and dilution.
Det anbefales, at den liposomale suspension blandes i et stinkskab/kabine med laminar-flow (LAF) med sterile handsker og under aseptiske forhold.
It is recommended that the reconstitution of the liposomal suspension should be performed in a laminar flow cabinet utilising sterile gloves using aseptic technique.
Hvis symptomerne varer længe eller forværres, bør du kontakte lægen, da behandlingen med MEPACT i så tilfælde måske skal udsættes eller afbrydes.
If you have long-lasting or worsening symptoms, you should contact your doctor, as MEPACT treatment may need to be delayed or discontinued.
Det niveau, hvor der ikke blev observeret bivirkninger af mifamurtid til dyr, svarer nogenlunde til den anbefalede dosis for mennesker på 2 mg/m
The no-adverse-effect level for mifamurtide in animals corresponds roughly to the 2 mg/m2 recommend dose for humans.
Fjern ikke filter-luerlock-forbindelseshætten på dette tidspunkt.
The filter luer connector cap should not be removed at this time.
Før behandlingen, bør du spørge din læge, om du skal tage din astmamedicin, mens du behandles med MEPACT.
Before using MEPACT, you should discuss with your doctor whether you should take medicine for your asthma when using MEPACT.
Let (50 ml/min ≤ kreatininclearance [CrCL] ≤ 80 ml/min) eller moderat (30 ml/min ≤ CrCL < 50 ml/min) nyreinsufficiens havde ingen effekt på clearance af total-MTP-PE ved sammenligning med raske voksne forsøgspersoner med normal nyrefunktion (CrCL > 80 ml/min).
There was no effect of mild (50 mL/min ≤ creatinine clearance [CLcr] ≤ 80 mL/min) or moderate (30 mL/min ≤ CLcr < 50 mL/min) renal insufficiency on the clearance of total MTP-PE, when compared with that observed in healthy adult subjects with normal renal function (CLcr > 80 mL/min).
Opløsningen må ikke opbevares i køleskab og må ikke nedfryses.
Do not refrigerate or freeze the solution.
In vivo indgivelse af mifamurtid resulterede i hæmmet tumorvækst i modeller af lungemetastase, hud- og leverkræft samt fibrosarcoma hos mus og rotter.
In vivo administration of mifamurtide resulted in the inhibition of tumour growth in mouse and rat models of lung metastasis, skin and liver cancer, and fibrosarcoma.
Sprøjten fjernes derefter fra filteret, og en ny kanyle sættes på sprøjten, som er fyldt med suspension.
The syringe should then be removed from the filter and a new needle placed on the suspension-filled syringe.
Du kan komme ud for mere alvorlige bivirkninger, herunder feber, kuldegysninger, træthed, kvalme, opkastning, hovedpine og for højt eller for lavt blodtryk.
You may experience more severe side effects, including fever, chills, fatigue, nausea, vomiting, headache and high blood pressure or low blood pressure.
• 1 steril engangs-luerlock-sprøjte til 60 eller 100 ml
• 1 single use 60 or 100 mL sterile syringe with luer lock
Uåbnet hætteglas med pulver
Unopened vial of powder
Efter opløsning i en natriumkloridopløsning på 9 mg/ml (0,9 %) opbevares blandingen ved stuetemperatur (ca. 20 ºC - 25 ºC) og anvendes inden for 6 timer.
Once reconstituted in sodium chloride 9 mg/mL (0.9%) solution, store at room temperature (approximately 20ºC - 25ºC) and use within 6 hours.
Andre generaliserede symptomer, der typisk var lette til moderate og meget almindelige, omfattede hypotermi (23 %), utilpashed (13 %), smerter (15 %), asteni (13 %) og smerter i brystet (11 %).
Other generalised symptoms that were typically mild to moderate and very common included hypothermia (23%), malaise (13%), pain (15%), asthenia (13%) and chest pain (11%).
Udslæt, pruritus, erythema, alopeci, tør hud
Rash, Pruritis, Erythema, Alopecia, Dry skin
Forstyrrelser i mave-tarmkanalen blev ofte forbundet med indgivelse af mifamurtid, herunder kvalme (57 %) og opkastning (44 %) hos ca. halvdelen af patienterne, forstoppelse (17 %), diarré (13 %) og smerter i maven (se pkt.
Gastrointestinal disorders were frequently associated with mifamurtide administration, including nausea (57%) and vomiting (44%) in about half of patients, constipation (17%), diarrhoea (13%) and abdominal pain (see section 4.4).
Pulver til koncentrat til infusionsvæske, dispersion 4 mg mifamurtid
Powder for concentrate for dispersion for infusion 4 mg mifamurtide
Det frysetørrede pulver skal rekonstitueres til en flydende suspension, som filtreres med brug af det medfølgende filter og yderligere fortyndes, før det indgives.
The freeze-dried powder has to be reconstituted into a liquid suspension, filtered using the filter provided and further diluted before use.
Meget almindelige bivirkninger (kan forekomme hos mere end 1 ud af 10 behandlede): - feber, rysten/kulderystelser, svaghed, træthed eller almindeligt ubehag - kvalme og/eller opkastning, diarré eller forstoppelse - hovedpine eller svimmelhed - hurtig puls - højt blodtryk eller lavt blodtryk - ingen appetit - svedafsondring - smerte, herunder generel smerte, smerter i muskler og/eller led og smerte i ryg, bryst, mave,
Very common side effects (may affect more than 1 in 10 people): - fever, shaking/shivering, weakness, tiredness or general discomfort - nausea and/or vomiting, diarrhoea or constipation - headache or dizziness - rapid beating of the heart - high blood pressure or low blood pressure - no appetite for food - sweating - pain, including general pain, pain in your muscles and/or joints and pain in back, chest,
Hyperhidrose (11 %) var meget almindelig hos patienter, der fik mifamurtid i ukontrollerede studier.
Skin and subcutaneous disorders Hyperhidrosis (11%) was very common in patients receiving mifamurtide in uncontrolled studies.
Du får MEPACT intravenøst (direkte i din vene) i løbet af ca. 1 time.
MEPACT is then infused directly into your vein (intravenous) over about 1 hour.
Samtidig anvendelse af høje doser non-steroide antiinflammatoriske lægemidler (NSAID'er, cyclooxygenase-hæmmere) (se pkt.
Concurrent use with high-dose non-steroidal-anti-inflammatory drugs (NSAIDs, cyclooxygenase inhibitors) (see section 4.5).
Anæmi indberettes meget ofte, når mifamurtidanvendes sammen med kemoterapi.
Anaemia has very commonly been reported when mifamurtide is used in conjunction with chemotherapeutic agents.
Mængden af opløst suspension, som svarer til den beregnede dosis, udvindes gennem det medfølgende filter og fortyndes yderligere med endnu en 50 ml natriumklorid 9 mg/ml (0,9 %) opløsning til injektion efter de detaljerede instruktioner nedenfor.
The volume of reconstituted suspension corresponding to the calculated dose is extracted through the filter provided and further diluted with additional 50 mL sodium chloride 9 mg/mL (0.9%) solution for injection according to the detailed instructions shown below.
Derfor kontraindiceres anvendelsen af højdosis NSAID-præparater (se pkt.
Therefore, the use of high-dose NSAIDs is contraindicated (see section 4.3).
Bivirkningerne er inden for hver enkelt frekvensgruppe opstillet efter, hvor alvorlige de er.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
• MEPACT pulver til koncentrat til infusionsvæske, dispersion (hætteglas)
• MEPACT powder for concentrate for dispersion for infusion (vial)
Der blev generelt observeret en højere procentdel af objektivt og subjektivt høretab hos patienter, som fik MEPACT og kemoterapi (henholdsvis 12 % og 4 %) i fase III-studiet (se en beskrivelse af studiet i pkt.
A higher percentage of objective and subjective hearing loss was observed overall in patients who received MEPACT and chemotherapy (12% and 4%, respectively) in the phase III study (see section 5.1 for a description of the study) compared to those patients that received only chemotherapy (7% and 1%).
For nemheds skyld medfølger denne dosistabel:
For convenience, the following table of concordance is provided:
Det anbefales at give MEPACT, doxorubicin eller andre typer medicin, der anvendes i samme kemoterapibehandling på forskellige tidspunkter.
It is recommended to separate the times of administration of MEPACT and doxorubicin or other medicines if used in the same chemotherapy treatment regimen.
Kvalme, opkastning og appetitløshed er meget almindelige bivirkninger af mifamurtid (se pkt.
Nausea, vomiting and loss of appetite are very common adverse reactions to mifamurtide (see section 4.8).
Til intravenøs brug efter rekonstitution, filtrering gennem det medfølgende filter og yderligere fortynding.
For intravenous use after reconstitution, filtering using the filter provided and further dilution.
Hvis mifamurtid anvendes, efter kemoterapien er afsluttet, anbefales det at fortsætte monitoreringen af nyre- og leverfunktionen, indtil hele behandlingen er afsluttet.
Continued monitoring of the kidney and liver function is recommended if mifamurtide is used beyond completion of chemotherapy until all therapy is completed.
smerter som efter en operation - muskelkramper eller stivhed - kuldefølelse - træthedfølelse, døsighed eller søvnighed - brænden, prikkende/snurrende følelse, nedsat følesans eller sådanne følelser uden stimulation - ufrivillig rysten - dehydrering - lav kaliumkoncentration i blodet - betændelse i slimhinder - tilstoppet næse, hals eller bihuler eller betændelse - infektioner i de øvre luftveje (som f.eks. en forkølelse) eller urinvejene (som f.eks. en blærebetændelse) - generel infektion - forkølelsessår - hoste med slim, hvæsende vejrtrækning eller besværet vejrtrækning ved anstrengelse - blodigt spyt eller næseblod - væske i lungehulrummet - blod i urinen, vanskelighed eller smerter ved vandladning eller hyppig vandladning - søvnbesvær, depression, ængstelighed eller forvirring - svimmelhed - ringen for øret - sløret syn - hårtab - vanskelig, smertefuld menstruation - høretab - et lavt antal hvide blodlegemer med eller uden feber, lavt antal blodplader
Common side effects (may affect up to 1 in 10 people): - blue colour of tissues such as the skin or gums caused by too little oxygen - perceptible increase in frequency or force of heartbeat - swelling in arms or legs or other swelling - chest discomfort - upset stomach, decreased appetite or weight loss - injection site or catheter site redness, swelling, infection or other local reaction - rash or redness, inflammation of the skin, itching, dry skin, pale or transient red appearance - inflammation of skin, tendons, muscles or similar tissues that support body structure - inflammation of a vein - upper abdominal or chest wall pain; abdominal bloating or pain; indigestion or pain in your liver - other pain, including neck, shoulder, groin, bone or throat pain; pain after an operation - muscle spasms or stiffness - feeling cold - tired feeling, drowsiness or sleepiness - burning, pricking/tingling sensation, diminished sensitivity to sensation or feeling a sensation without stimulus - involuntary shaking movement - dehydration - low concentration of potassium in blood - mucosal inflammation - nose, throat, or sinus congestion or inflammation - infections of the upper respiratory tract (such as a cold) or the urinary tract (such as a bladder infection) - generalised infection - Herpes simplex (virus) infection - productive cough, wheezing or exertional or exacerbated shortness of breath - spitting of blood or nosebleed - fluid in the lung cavity - blood in urine, difficulty or pain in urination or frequent urination - difficulty sleeping, depression, anxiety or confusion - dizziness - ears ringing - blurred vision - hair loss - difficult, painful menstruation - hearing loss - low number of white blood cells with or without fever, low number of platelets
2 Mepact indeholder natrium”.
See section 2 “MEPACT contains sodium”
Udseende og pakningsstørrelser MEPACT er et hvidt eller off-white ensartet pulver til koncentrat til infusionsvæske, dispersion.
What MEPACT looks like and contents of the pack MEPACT is a white to off-white homogeneous cake or powder for concentrate for dispersion for infusion.
Mifamurtids farmakokinetik efter en enkelt dosis på 4 mg givet over 1 time som intravenøs infusion blev evalueret hos voksne frivillige forsøgspersoner med let (n = 9) eller moderat (n = 8) nyreinsufficiens og hos raske voksne med normal nyrefunktion, der matchede i alder og vægt (n = 16).
The pharmacokinetics of a single 4 mg dose of mifamurtide following a 1 hour intravenous infusion were evaluated in adult volunteers with mild (n = 9) or moderate (n = 8) renal impairment and in age-, sex-, and weight-matched healthy adults with normal renal function (n = 16).
Man ved ikke, om MEPACT udskilles i modermælk.
It is not known whether MEPACT passes to human milk.
Blodforgiftning, cellulitis, nasofaryngitis, infektion på kateterstedet, infektion i de øvre luftveje, urinvejsinfektion, faryngitis, Herpes simplex-infektion
Sepsis, Cellulitis, Nasopharyngitis, Catheter site infection, Upper respiratory tract infection, Urinary tract infection, Pharyngitis, Herpes simplex infection
Mifamurtids farmakokinetik efter en enkelt 4 mg dosis mifamurtid givet over 1 time som intravenøs infusion blev evalueret hos voksne frivillige forsøgspersoner med let (Child-Pugh klasse A; n = 9) eller moderat (Child-Pugh klasse B; n = 8) leverinsufficiens og hos raske voksne med normal leverfunktion, der matchede i alder og vægt (n = 19).
The pharmacokinetics of a single 4 mg dose of mifamurtide following a 1 hour intravenous infusion were evaluated in adult volunteers with mild (Child-Pugh class A; n = 9) or moderate (Child-Pugh class B; n = 8) hepatic impairment and in age, sex-, and weight-matched healthy adults with normal hepatic function (n = 19).
Hvis du ammer, skal du tale med lægen.
If you are breast-feeding, you should discuss with your doctor.
Rens det sted på posen, hvor kanylen indføres med en spritpude, og sprøjt suspensionen i sprøjten ind i den oprindelige pose, som indeholder de resterende 50 ml af natriumklorid 9 mg/ml (0,9 %) injektionsopløsning (figur 4).
The bag injection site should be wiped with an alcohol pad and the suspension in the syringe should be injected into the original bag containing the remaining 50 mL of sodium chloride 9 mg/mL (0.9%) solution for injection (figure 4).
Lette smerter var meget almindelig hos patienter, der fik mifamurtid, herunder myalgi (31 %), rygsmerter (15 %), ekstremitetssmerter (12 %) og artralgi (10 %).
Musculoskeletal and connective tissue disorders Low grade pain was very common in patients receiving mifamurtide, including myalgia (31%), back pain (15%), extremity pain (12%) and arthralgia (10%).
Hæmaturi, dysuri, pollakisuri
Haematuria, Dysuria, Pollakiuria
Den 9 mg/ml (0,9 %) injektionsopløsning af natriumklorid føjes til hætteglasset ved at trykke sprøjtens stempel ned med en langsom, fast bevægelse.
The sodium chloride 9 mg/mL (0.9%) solution for injection is added to the vial by slow, firm depression of the syringe plunger.
Desuden svarede den systemiske eksponering AUCinf (arealet under kurven fra nul til uendelig) for fri (ikke-liposom-associeret) MTP-PE hos personer med let eller moderat nyreinsufficiens til eksponeringen hos raske voksne forsøgspersoner med normal nyrefunktion.
Additionally, the systemic exposures AUC from zero to infinity (AUCinf of free (non-liposome associated) MTP-PE in mild or moderate renal insufficiency were similar to those observed in healthy adult subjects with normal renal function.
Paræstesi, hypæstesi, tremor, døsighed, letargi
Paraesthesia, Hypoaesthesia, Tremor, Somnolence, Lethargy
Lægemidlet må kun udleveres efter ordination på en særlig recept udstedt af en begrænset lægegruppe (se bilag I: Produktresumé, pkt.
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Mængde
Volume
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine mononatriumsalt (OOPS)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine monosodium salt (OOPS)
Sådan skal du bruge MEPACT
How to use MEPACT
De hyppigste bivirkninger er kulderystelser, feber, træthed, kvalme, takykardi og hovedpine.
The most frequent adverse reactions are chills, pyrexia, fatigue, nausea, tachycardia and headache.
Fjern filteret fra blisterpakken og låget fra filterspidsen.
The filter should be removed from the blister pack, and the cap removed from the filter spike.
MEPACT skal under aseptiske forhold opløses, filtreres gennem det medfølgende filter og fortyndes yderligere før administration.
MEPACT must be reconstituted, filtered using the filter provided and further diluted using aseptic technique, prior to administration.
Samtidig anvendelse af ciclosporin eller andre calcineurinhæmmere (se pkt.
Concurrent use with ciclosporin or other calcineurin inhibitors (see section 4.5).
Smerter i øverste del af maven, dyspepsi, abdominal distension, smerter i nederste del af maven
Upper abdominal pain, Dyspepsia, Abdominal distension, Lower abdominal pain
MEPACT-behandlingen giver i mange tilfælde bivirkninger (som svimmelhed, træthed og sløret syn), som kan påvirke arbejdssikkerheden og evnen til at færdes sikkert i trafikken.
Some very common and common side effects of MEPACT treatment (such as dizziness, vertigo, fatigue and blurred vision) may affect your ability to drive and use machines.
Hvert hætteglas indeholder 4 mg mifamurtid.
Each vial contains 4 mg of mifamurtide.
Pleural effusion, forværret dyspnø, produktiv hoste, hæmoptyse, hvæsende vejrtrækning, epistaxis, anstrengelsesdyspnø, tilstoppede bihuler, tilstoppet næse, pharyngolaryngeal smerte
Pleural effusion, Exacerbated dyspnoea, Productive cough, Haemoptysis, Wheezing, Epistaxis, Exertional dyspnoea, Sinus congestion, Nasal congestion, Pharyngolaryngeal pain
Hjælpestoffer: Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-Dioleoylsn-glycero-3-phospho-L-serine mononatriumsalt (OOPS)
Excipients: Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine monosodium salt (OOPS)
Det er ikke undersøgt, hvorvidt mifamurtid udskilles i modermælken hos dyr.
The excretion of mifamurtide in milk has not been studied in animals.
MEPACT 4 mg pulver til koncentrat til infusionsvæske, dispersion.
MEPACT 4 mg powder for concentrate for dispersion for infusion
Pakke med 1 hætteglas pulver, 1 sterilt filter
Powder for concentrate for dispersion for infusion Pack of 1 vial of powder, 1 sterile filter
Fjern hætteglassets låg, og rens proppen med en spritpude.
The cap of the vial should be removed and the stopper cleaned using an alcohol pad.
Feber, kulderystelser, træthed, hypotermi, smerter, utilpashed, asteni, brystsmerter
Fever, Chills, Fatigue, Hypothermia, Pain, Malaise, Asthenia, Chest pain
Hvert4 mg hætteglas indeholder 4 mg mifamurtid*.
Each vial contains 4 mg mifamurtide*.
Hvert hætteglas skal blandes med 50 ml natriumklorid 9 mg/ml (0,9 %) injektionsopløsning.
Each vial should be reconstituted with 50 mL of sodium chloride 9 mg/mL (0.9%) solution for injection.
Derfor bør produktresuméet for mifamurtid opdateres med indsættelse af perikardieekssudat som bivirkning i pkt.
Therefore, the SmPC of mifamurtide should be updated with the inclusion of pericardial effusion as an ADR in section 4.8 under SOC Cardiac disorders.
Derfor må hverken gravide eller kvinder i den fødedygtige alder, der ikke bruger sikker prævention, behandles med MEPACT.
Therefore, MEPACT should not be used during pregnancy and in women of childbearing potential not using effective contraception.
- Øvrige indholdsstoffer: 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) og 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine mononatriumsalt (OOPS), se pkt.
- The other ingredients are 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine monosodium salt (OOPS).
Smerter efter indgreb
Post-procedural pain
Pak 100 ml natriumklorid 9 mg/ml (0,9 %) opløsning til injektionsposen, kanyle og sprøjte ud (følger ikke med pakken).
The 100 mL sodium chloride 9 mg/mL (0.9%) solution for injection bag, needle and syringe should be unpacked (not provided in the pack).
Perifert ødem, ødem, slimhindebetændelse, erythema på infusionsstedet, reaktion på infusionsstedet, smerte på kateterstedet, brystsmerter, kuldefølelse
Peripheral oedema, Oedema, Mucosal inflammation, Infusion site erythema, Infusion site reaction, Catheter site pain, Chest discomfort, Feeling cold
Cancersmerte
Cancer pain
Pulver til koncentrat til infusionsvæske, dispersion.
Powder for concentrate for dispersion for infusion
Brug af anden medicin sammen med MEPACT Fortæl det altid til lægen, hvis du bruger anden medicin, har gjort det for nylig, eller overvejer at gøre det.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
5.2), og da der er begrænsede sikkerhedsdata for patienter med moderat leverinsufficiens, anbefales forsigtighed ved administration af mifamurtid til patienter med moderat leverinsufficiens.
However, as the variability in pharmacokinetics of mifamurtide is greater in subjects with moderate hepatic impairment (see section 5.2), and safety data in patients with moderate hepatic impairment is limited, caution when administering mifamurtide to patients with moderate hepatic impairment is recommended.
Ved hjælp af kanylen og sprøjten trækkes injektionsopløsningen med 50 ml natriumklorid 9 mg/ml (0,9 %) ud af posen.
Using the needle and syringe, 50 mL of sodium chloride 9 mg/mL (0.9%) solution for injection should be withdrawn from the bag.
Opkastning, diarré, obstipation, mavesmerter, kvalme
Vomiting, Diarrhoea, Constipation, Abdominal pain, Nausea
Dyspnø, takypnø, hoste
Dyspnoea, Tachypnoea, Cough
Hvis du har brugt for meget MEPACT
If you use more MEPACT than you should
Patientidentifikation, tid og dato påføres på posens etiket.
Patient identification, time and date should be added to the label on the bag containing the reconstituted, filtered and diluted liposomal suspension.
Myalgi, artralgi, rygsmerter, smerter i ekstremiteterne
Myalgia, Arthralgia, Back pain, Pain in extremity
Muskelspasmer, nakkesmerter, lyskesmerter, knoglesmerter, skuldersmerter, smerter i thoraxvæg, muskuloskeletal stivhed
Muscle spasms, Neck pain, Groin pain, Bone pain, Shoulder pain, Chest wall pain, Musculoskeletal stiffness
Hvis du behandles med MEPACT, skal du bruge sikker prævention.
You should use effective contraception if you are being treated with MEPACT.
Det skal du vide, før du begynder at bruge MEPACT Sådan skal du bruge MEPACT Bivirkninger
What MEPACT is and what it is used for What you need to know before you use MEPACT How to use MEPACT
Hver ml opløst suspension indeholder 0,08 mg/ml mifamurtid.
Each mL reconstituted suspension contains 0.08 mg mifamurtide.
Rens det sted på posen med den 100 ml natriumklorid 9 mg/ml (0,9 %) injektionsopløsning, hvor kanylen skal indføres med en spritpude.
The site of the sodium chloride 9 mg/mL (0.9%) solution for injection bag where the needle is going to be inserted should be swabbed with an alcohol pad.
Flebitis, rødmen, bleghed
Phlebitis, Flushing, Pallor
MEPACT leveres i en pakning, der indeholder
What MEPACT is and what it is used for
Indfør derefter spidsen i hætteglassets skillevæg, indtil den sidder fast.
The spike should then be inserted into the vial septum firmly until seated.
Efter rekonstitution indeholder hver ml suspension i hætteglasset 0,08 mg mifamurtid.
After reconstitution, each mL suspension in the vial contains 0.08 mg mifamurtide.
Efter blanding indeholder hver ml opløsning 0,08 mg mifamurtid.
After reconstitution, each mL of suspension contains 0.08 mg of mifamurtide.
Sådan bliver du behandlet med MEPACT
How MEPACT is given